GENINUS Inc. (389030.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩1,335 (-4.16%) as of
Key statistics
- Market cap
- 52.59B
- Dividend yield
- 0.00%
- 52-week range
- 1,322.00 – 6,480.00
- Beta
- 0.14
- Revenue (TTM)
- 11.28B
- Profit margin
- -180.50%
- Volume
- 456.33k
About GENINUS Inc.
GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of genome analysis solutions in South Korea, the United States, and Asia. It offers tarhet and biomarker discovery; AI digital pathology; single cell analysis; and spatial and in-situ transcriptomics services; and SPACEINSIGHT, a cutting-edge cloud based integrated analysis platform. It serves hospitals, pharmaceutical companies, and researchers. The company was founded in 2018 and is headquartered in Seoul, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Seoul, South Korea
- Employees
- 60
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.